These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35216261)

  • 21. Correction: Funk et al. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
    Funk F; Flühmann B; Barton AE
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fe(III).ATP complexes. Models for ferritin and other polynuclear iron complexes with phosphate.
    Mansour AN; Thompson C; Theil EC; Chasteen ND; Sayers DE
    J Biol Chem; 1985 Jul; 260(13):7975-9. PubMed ID: 2989269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous Irons: From Basic Science to Clinical Practice.
    Bhandari S; Pereira DIA; Chappell HF; Drakesmith H
    Pharmaceuticals (Basel); 2018 Aug; 11(3):. PubMed ID: 30150598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of iron salts and ferric hydroxide-carbohydrate complexes.
    Geisser P; Müller A
    Arzneimittelforschung; 1987 Jan; 37(1A):100-4. PubMed ID: 3566862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
    Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
    Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
    Cozzolino M; Funk F; Rakov V; Phan O; Teitelbaum I
    Curr Drug Metab; 2014; 15(10):953-65. PubMed ID: 25658128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver.
    Spicher K; Brendler-Schwaab S; Schlösser C; Catarinolo M; Fütterer S; Langguth P; Enzmann H
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):65-72. PubMed ID: 26111606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of the intravenous administration of cytochrome c or of ferric iron upon the oxygen debt in heart patients.
    POPPI A; MARTINELLI M
    Cardiologia (Basel); 1952; 21(4):718-26. PubMed ID: 13019827
    [No Abstract]   [Full Text] [Related]  

  • 29. Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
    Hempel JC; Poppelaars F; Gaya da Costa M; Franssen CF; de Vlaam TP; Daha MR; Berger SP; Seelen MA; Gaillard CA
    Am J Nephrol; 2017; 45(1):49-59. PubMed ID: 27889746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The intravenous use of high molecular ferric carbohydrate compound in the treatment of hypochromic anemia.
    LUCAS JE; HAGEDORN AB
    Blood; 1952 Mar; 7(3):358-67. PubMed ID: 14904518
    [No Abstract]   [Full Text] [Related]  

  • 31. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
    Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
    Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biodistribution, Clearance And Morphological Alterations Of Intravenously Administered Iron Oxide Nanoparticles In Male Wistar Rats.
    Gaharwar US; Meena R; Rajamani P
    Int J Nanomedicine; 2019; 14():9677-9692. PubMed ID: 31827324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [On the problem of the effect of feeding of iron saccharate on the mutation rate induced by roentgen rays in Drosophila melanogaster].
    TRAUT H
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1960; 91():325-32. PubMed ID: 13777913
    [No Abstract]   [Full Text] [Related]  

  • 34. Iron polymaltose complexes: Could we spot physicochemical differences in medicines sharing the same active pharmaceutical ingredient?
    Di Francesco T; Delafontaine L; Philipp E; Lechat E; Borchard G
    Eur J Pharm Sci; 2020 Feb; 143():105180. PubMed ID: 31841697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Optimized Process for the Preparation of Aqueous Ferric Carboxymaltose: Synthesis and Structural Characterization.
    Tabasi O; Razlighi MR; Darbandi MA
    Pharm Nanotechnol; 2021; 9(2):157-163. PubMed ID: 33459254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations.
    Kudasheva DS; Lai J; Ulman A; Cowman MK
    J Inorg Biochem; 2004 Nov; 98(11):1757-69. PubMed ID: 15522403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polynuclear iron complexes impair the function of polymorphonuclear granulocytes.
    Hoepelman IM; Jaarsma EY; Verhoef J; Marx JJ
    Br J Haematol; 1988 Mar; 68(3):385-9. PubMed ID: 3355798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products.
    Zou P; Tyner K; Raw A; Lee S
    AAPS J; 2017 Sep; 19(5):1359-1376. PubMed ID: 28762128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats.
    Geisser P; Müller A
    Arzneimittelforschung; 1984; 34(11):1560-9. PubMed ID: 6543131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.